table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
cilgavimab and tixagevimab (Evusheld) PROVENT

1 studies excluded by filtering options 0

9866 Jurdi, 2022 1110not a RCTrisk of bias not avaialble

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons